Moderna secured a pivotal legal victory in the UK Court of Appeals, which upheld the validity of its EP’949 patent concerning modified nucleotides in mRNA COVID-19 vaccines. The ruling denies Pfizer and BioNTech's attempts to revoke this patent, affirming infringement by their Comirnaty vaccine. This decision strengthens Moderna's intellectual property position globally and impacts ongoing patent disputes in multiple jurisdictions. Moderna's CEO emphasized continued enforcement efforts to protect its mRNA technology.